Product Information
RHOPRESSA 0.02% OPHTH SOLUTION is a brand product labeled by Alcon Laboratories, Inc., priced at $131.6761 per ML under NDC 70727049725. Its NADAC has been published 416 times since Oct 17, 2018.
FDA first approved this application on Dec 18, 2017.
Strength
.2 mg/mL
Manufacturer
Alcon Laboratories, Inc.NDC
70727049725
Classification
Brand
Dosage Form
SOLUTION/ DROPS
Route
OPHTHALMIC; TOPICAL
Effective Date
9/23/2026
Active Ingredients
NETARSUDIL MESYLATEApproval Type
New Drug (NDA)
FDA Application
NDA208254FDA Approved
12/18/2017
On Market Since
12/18/2017
Pharmacological Classes
Price Statistics
The NADAC for RHOPRESSA 0.02% OPHTH SOLUTION has been published 416 times since Oct 17, 2018, and over the history we have for it it has risen 50.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $131.6761 per ML |
|---|---|
| All-time high | $131.9200 (May 13, 2026) |
| All-time low | $87.7131 (Oct 17, 2018) |
| 52-week high | $131.9200 |
| 52-week low | $128.0494 |
| Median price | $114.0860 |
| Average price | $114.9979 |
| Largest weekly change | +9.0% (Nov 28, 2018) |
| Weeks tracked | 416 |
| Tracking since | Oct 17, 2018 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the netarsudil market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Alcon Laboratories, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
netarsudil market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RHOPRESSA 0.02% OPHTH SOLUTION?
The current National Average Drug Acquisition Cost (NADAC) for RHOPRESSA 0.02% OPHTH SOLUTION, manufactured by Alcon Laboratories, Inc., is $131.6761 per ML (NDC 70727049725), effective Sep 30, 2026.
How has the price of RHOPRESSA 0.02% OPHTH SOLUTION changed over time?
Over the history we have for it, the NADAC for RHOPRESSA 0.02% OPHTH SOLUTION has risen 50.1%. It has been tracked across 416 weekly CMS publications since Oct 17, 2018.
What are the highest and lowest recorded NADAC prices for RHOPRESSA 0.02% OPHTH SOLUTION?
Since Oct 17, 2018, the NADAC for RHOPRESSA 0.02% OPHTH SOLUTION has ranged from a low of $87.7131 (Oct 17, 2018) to a high of $131.9200 (May 13, 2026), with a median of $114.0860 per ML.
Are there cheaper alternatives to RHOPRESSA 0.02% OPHTH SOLUTION?
No other NADAC-published product currently shares the active ingredient and strength of RHOPRESSA 0.02% OPHTH SOLUTION in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures RHOPRESSA 0.02% OPHTH SOLUTION?
RHOPRESSA 0.02% OPHTH SOLUTION (NDC 70727049725) is labeled by Alcon Laboratories, Inc., and CMS classifies it as a brand product.